ORIC Pharmaceuticals, Inc. (ORIC) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 10 Buy.
The consensus price target is $21.75 (low: $15.00, high: $25.00), representing an upside of 106.6% from the current price $10.53.
Analysts estimate Earnings Per Share (EPS) of $-1.85 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.83 vs est $-1.85 (beat +1.2%). 2025: actual $-1.47 vs est $-1.52 (beat +3.1%). Analyst accuracy: 98%.
ORIC Stock — 12-Month Price Forecast
$21.75
▲ +106.55% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for ORIC Pharmaceuticals, Inc., the average price target is $21.75, with a high forecast of $25.00, and a low forecast of $15.00.
The average price target represents a +106.55% change from the last price of $10.53.
Highest Price Target
$25.00
Average Price Target
$21.75
Lowest Price Target
$15.00
ORIC Analyst Ratings
Buy
Based on 10 analysts giving stock ratings to ORIC Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — ORIC
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.83
vs Est –$1.85
▲ 1.2% off
2025
Actual –$1.47
vs Est –$1.52
▲ 3.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ORIC
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
